Abstract
Accurately estimating relative transmission rates of SARS-CoV-2 variants remains a scientific and public health priority. Recent studies have used the sample proportions of different variants from genetic sequence data to describe variant frequency dynamics and relative transmission rates, but frequencies alone cannot capture the rich epidemiological behavior of SARS-CoV-2. Here, we extend methods for inferring the effective reproduction number of an epidemic using confirmed case data to jointly estimate variant-specific effective reproduction numbers and frequencies of co-circulating variants using cases and sequences across states in the US from January 2021 to March 2022. Our method can be used to infer structured relationships between effective reproduction numbers across time series allowing us to estimate fixed variant-specific growth advantages. We use this model to estimate the effective reproduction number of SARS-CoV-2 Variants of Concern and Variants of Interest in the United States and estimate consistent growth advantages of particular variants across different locations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
MF is an ARCS Foundation scholar and was supported by the National Science Foundation Graduate Research Fellowship Program under Grant No.\ DGE-1762114. TB is an Investigator of the Howard Hughes Medical Institute. This project was supported by funds from the HHMI COVID-19 Collaboration Initiative awarded to the Fred Hutchinson Cancer Research Center and the University of Washington.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Case count data was obtained from the US CDC using the `United States COVID-19 Cases and Deaths by State over Time' dataset available from \href{https://data.cdc.gov/Case-Surveillance/United-States-COVID-19-Cases-and-Deaths-by-State-o/9mfq-cb36}{data.cdc.gov}. Sequence data including date and location of collection as well as clade annotation was obtained via the Nextstrain-curated `open' dataset \cite{Hadfield2018} that pulls from sequences shared to NCBI GenBank. Raw sequence data is available from \href{https://docs.nextstrain.org/projects/ncov/en/latest/reference/remote_inputs.html}{data.nextstrain.org}.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We've cut the wave-size analysis, updated the text in several places for clarity, and re-focused parts on the method instead of the epidemiological results, re-framing the applicability as case counts decline.
Data Availability
Derived data of sequence counts and case counts, along with all source code used to analyze this data and produce figures is available via the GitHub repository \href{https://github.com/blab/rt-from-frequency-dynamics/}{github.com/blab/rt-from-frequency-dynamics}.
